Ciphergen Stock Tanks 27.2 Percent as Firms Cuts Q1 Sales Outlook in Half | GenomeWeb

NEW YORK, April 5 (GenomeWeb News) - Shares in Ciphergen were down 27.24 percent, or $.67, at $1.79 in early-afternoon trading after the company said lackluster sales will cause first-quarter revenue to fall significantly short of earlier expectations.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.